- Home
- ANGO vs VSTM Comparison
ANGO vs VSTM Comparison
Compare ANGO & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- VSTM
- Stock Information
- Founded
- ANGO 1988
- VSTM 2010
- Country
- ANGO United States
- VSTM United States
- Employees
- ANGO N/A
- VSTM N/A
- Industry
- ANGO Medical/Dental Instruments
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- VSTM Health Care
- Exchange
- ANGO Nasdaq
- VSTM Nasdaq
- Market Cap
- ANGO 439.5M
- VSTM 425.9M
- IPO Year
- ANGO 2004
- VSTM 2012
- Fundamental
- Price
- ANGO $10.09
- VSTM $7.08
- Analyst Decision
- ANGO Strong Buy
- VSTM Strong Buy
- Analyst Count
- ANGO 2
- VSTM 9
- Target Price
- ANGO $14.00
- VSTM $13.63
- AVG Volume (30 Days)
- ANGO 422.1K
- VSTM 2.1M
- Earning Date
- ANGO 07-15-2025
- VSTM 05-13-2025
- Dividend Yield
- ANGO N/A
- VSTM N/A
- EPS Growth
- ANGO N/A
- VSTM N/A
- EPS
- ANGO N/A
- VSTM N/A
- Revenue
- ANGO $283,320,000.00
- VSTM $10,000,000.00
- Revenue This Year
- ANGO N/A
- VSTM $106.87
- Revenue Next Year
- ANGO $6.35
- VSTM $312.95
- P/E Ratio
- ANGO N/A
- VSTM N/A
- Revenue Growth
- ANGO N/A
- VSTM N/A
- 52 Week Low
- ANGO $5.47
- VSTM $2.10
- 52 Week High
- ANGO $13.50
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- ANGO 58.79
- VSTM 47.31
- Support Level
- ANGO $9.78
- VSTM $7.60
- Resistance Level
- ANGO $10.40
- VSTM $9.10
- Average True Range (ATR)
- ANGO 0.35
- VSTM 0.88
- MACD
- ANGO 0.10
- VSTM -0.09
- Stochastic Oscillator
- ANGO 76.69
- VSTM 33.16
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.